PEPTINOV’s Post

📽️ Introducing Argent BioPharma’s Vision for the Future 📽️ We’re excited to share our journey in transforming healthcare through innovation. Our focus on addressing CNS conditions and immunology is driven by our commitment to advancing treatments for unmet medical needs. Watch the video to learn more about our vision and innovative approach!💡 #argentbiopharma #innovation #development

How good are European health systems in publishing real-world data (#RWD) on #quality indicators? A new IHE report looks at the example of drug #treatment rates in advanced-stage non-small cell lung cancer (#NSCLC). As illustrated in the map, our review of published data finds a pronounced absence of reliable, comprehensive, up-to-date data. #Sweden and the #UK emerged as best-practice examples, yet even in these countries the published data are not granular enough to get a full picture of the quality of treatment provided. The review of published RWD studies also shows that recent advances in the medical treatment of NSCLC may not be fully utilized in clinical settings. It is common to observe an underuse of newer treatments options (#immunotherapy and #targetedtherapy) and an overuse of older treatment options (#chemotherapy) compared to recommendations in ESMO clinical guidelines. This report follows in the footsteps of a previous IHE report that estimated drug treatment rates in NSCLC for 12 countries and provided a qualitative analysis of reasons for sub-optimal treatment rates (Link: https://lnkd.in/dikj8USE)). It also responds to a Call to Action - Fighting lung cancer together as equals - that a group of stakeholders under the patronage of MEP Cristian-Silviu Bușoi issued in December 2022 (Link: https://lnkd.in/eD86Gpi8). 👉 Download the new IHE report here: https://lnkd.in/dJ5G78Xi

🎉Exciting News in Chronic GvHD Treatment!🎉 On August 14, 2024, Incyte and Syndax announced FDA approval of Niktimvo™ (axatilimab-csfr), the first CSF-1R monoclonal antibody approved for treating chronic graft-versus-host disease (GvHD) in patients unresponsive to at least two prior therapies. Specifically, Niktimvo helps to mitigate the chronic inflammatory and fibrotic responses characteristic of this condition. At Biocytogen, we are committed to supporting the scientific community with advanced research tools. We have developed a range of GvHD mouse models leveraging our proprietary B-NDG immunodeficient mice and humanized mouse models based on these B-NDG mice. These models offer critical insights into immune responses, facilitating the development of novel treatments. 🐭 Contact us today to explore how our GvHD mouse models can advance your research and contribute to the future of GvHD treatment! 💡Read more: https://lnkd.in/gVw5eUAR #GvHD #Immunology #Biotech #HealthcareInnovation #FDAApproval #ResearchTools #Biocytogen

Alzinova AB confirms positive top-line results!   We are thrilled to announce that the primary analysis of our phase 1b clinical trial for Alzheimer's disease has confirmed the positive top-line results for our vaccine candidate, ALZ-101! It reveals that ALZ-101 was not only well-tolerated and safe but also triggered a high frequency of immune response and patients treated with ALZ-101 exhibited increasing antibody levels with each dose.   Kristina Torfgård, our CEO, states, "The full analysis validates ALZ-101 as a promising vaccine candidate against Alzheimer's disease, meeting our primary objective of safety and tolerability. These results, along with the positive antibody response, position us well for potential partnerships. We eagerly anticipate sharing these findings with interested collaborators."   Key Highlights from the phase 1b study: 🔬 Favorable safety and tolerability profile observed across all dose groups. 🧠 High frequency of immune response, with increased antibody levels. 💡 Positive results pave the way for potential optimization and higher doses.   Looking Ahead: ➡️ Exploration of treatment effects on biomarkers and cognition, with results expected in the extension part of the study (part B) in the first half of 2025. ➡️ Additional dose arm evaluating a higher dose (400 μg) in an open-label format. ➡️ Preparations ahead of phase 2 ongoing as planned.   Publication and Presentation: 📄 A scientific article detailing the study results will be submitted to a medical journal for publication. 🎙️ Results are scheduled to be presented at upcoming international medical conferences.   Learn more on our website, link in comments!   #AlzheimersResearch #InnovationInHealthcare #ALZ101 #ClinicalTrials #MedicalBreakthroughs

Missed the webinar? Check out the recording here: https://lnkd.in/gBTNF_9t Between live and fixed sample processing on our 25 marker spectral flow panel, we found (across 36 phenotypic populations, and 62 state marker subtypes): * 0.97 correlation of population frequencies * 0.91 correlation of state marker-positive subset frequencies Who cares? Immunotherapy developers struggling with the 10-20% failure rate for fresh specimens on trials. Big wins here: 1. Most obviously, ~10-20X reduction of failure rate through centralization of flow analysis. No need for a flow lab in every geography. Reduce variability by having all samples processed by the same facility. 2. Prospectively batch samples on spectral flow: You can store fixed samples until a whole set (for example all timepoints of an individual patient) is complete. 3. Reduce your committed processing cost and expand your analysis window. If you don't know upfront which samples to analyze, store your samples at -80C until you’re ready to decide.

Blue Book of Disease Registries (DR), released in May 2024. There are some interesting facts in the book, i.e., till 3/9/2024, there are 5981 observational studies registered at clinicaltrials.gov, among them, 2937 are DRs. The top three diseases areas, Cardiovascular (30%), cancer (14%) and CNS (6%). Academia leads 64% DR studies, industries 28%. How are DRs used? 1. to generate supplemental evidence for trials; 2. assist trial design, 3. ECA, 4. Natural history, 5. PMS/PV, 6. HEOR, 7. Innovation in trials, such as registry-embedded trials, 8. Patient Focused Drug Development. I will give a workshop next month, comparing DRs between US and China.

Our commitment to the global sustainable development agenda is at the core of our mission: transforming the lives of people living with rare and debilitating diseases. Our sustainability strategy is integrated into our business and focuses on two main priorities: maintaining our commitment to patients and always acting responsibly. By expanding our geographical reach, investing in the development of innovative medicines, and deepening our engagement in haematology, immunology, and specialty care, we are enhancing access to rare disease treatments for patients around the world, step by step. Learn more about our commitments to patients. https://lnkd.in/e6cSjDP4 #Sobi #RareDiseases #Sustainability

Naresh Bumma, The Ohio State University, Columbus, US, presented on BCMA-directed bispecific antibodies during the Multiple Myeloma Hub’s recent symposium. Some of the latest data from the EHA, ASCO, and ASH congresses were explored, with a focus on differences between agents and biomarkers of response. Bumma then discussed the integration of BCMA-directed antibodies into the current #MultipleMyeloma landscape, finishing with a real case example to emphasize their applicability to clinical practice. “We need to consider patient-specific clinical factors. Access is very important, and obviously patient preference is very important” Click the link below to catch up 👇 https://loom.ly/3ZEBvZE #bispecific #myeloma #mmsm

🎉 Thank you to everyone who joined our LIVE virtual discussion on Systems Immunology! In case you missed it, or want to watch it again, here's the link to the recording: https://lnkd.in/gw-dWv3n Don't forget, you can also review our April webinar! Stay tuned for more upcoming events from PLMI! #PLMI #predictivemedicine #systemsimmunology #freeevent #integrativemedicine #integrativehealth #functionalmedicine

Is FcyR activity convoluting your immunology study? Find better answers using fewer resources with FcResolv® hIL-15 NOG mice where these FcγRs are absent. Learn More: https://bit.ly/4cRyoXd